INTRODUÃÃO - A gripe à uma doenÃa infecciosa aguda de origem viral, de distribuiÃÃo universal, que acomete o trato respiratÃrio. Segundo estatÃsticas da OrganizaÃÃo Mundial da SaÃde (OMS), cerca de 5 a 15% da populaÃÃo mundial se infecta com o vÃrus da influenza anualmente. Em marÃo de 2009, com mudanÃa no padrÃo da ocorrÃncia da influenza no MÃxico, o vÃrus da influenza A (H1N1), um quÃdruplo recombinante nunca antes visto, foi identificado atravÃs da anÃlise de amostras de secreÃÃo de nasofaringe de crianÃas americanas sintomÃticas, confirmando o vÃnculo epidemiolÃgico com os casos no MÃxico (CDC/Atlanta, 2009) e em meses seguintes, com a transmissÃo sustentada de pessoa para pessoa e acometimento de vÃrios paÃses e naÃÃes, foi deflagrada uma nova pandemia. OBJETIVOS - Os objetivos deste estudo foram descrever a evoluÃÃo temporal, caracterizar os padrÃes de morbi-mortalidade e identificar os fatores associados à ocorrÃncia de gravidade e Ãbitos nas diferentes fases da pandemia de Influenza A (H1N1) 2009 no CearÃ. MÃTODOS - Trata-se de estudo descritivo, retrospectivo, dos casos notificados e confirmados de influenza pandÃmica (H1N1) 2009, no Estado do CearÃ, nos anos de 2009 e 2010. RESULTADOS E DISCUSSÃO - A pandemia deu-se em trÃs pequenas ondas, uma na fase de contenÃÃo, caracterizada por casos leves, com resoluÃÃo rÃpida. As duas segundas ondas, na fase de mitigaÃÃo, com casos com maior gravidade, maior taxa de hospitalizaÃÃo, a totalidade de pacientes que necessitaram de cuidados intensivos (UTI) e todos os pacientes que evoluÃram para Ãbito. Foram notificados 615 casos, destes 144 foram confirmados. 55,5% eram do sexo feminino, 30% eram pardos, 72,5% dos casos graves possuÃam alguma comorbidade e 40 pacientes necessitaram de hospitalizaÃÃo. A letalidade hospitalar foi de 20% e a letalidade em UTI foi de 66%. Foram significantes para evoluÃÃo para cura ou Ãbito aspectos relacionados à procura por assistÃncia mÃdica, atraso no inÃcio da terapia antiviral, obesidade, ter baixa escolaridade, uso de ventilaÃÃo mecÃnica e ser hospitalizado em hospitais com atendimento especializado. CONCLUSÃO - A anÃlise dos dados do presente estudo permitiu conhecimento aprofundado acerca do padrÃo de morbi-mortalidade causado pela pandemia de influenza A (H1N1) 2009 no Estado do CearÃ. O estudo sugere que a pandemia de influenza A (H1N1) 2009 nesta regiÃo do Brasil teve magnitude menor se comparado a outros estados de outras regiÃes do paÃs, com baixa incidÃncia, porÃm altas taxas de letalidade em pacientes internados em UTI. / NTRODUCTION - Influenza is an acute infectious disease of viral origin, universal distribution, which affects the respiratory tract. According to statistics from the World Health Organization (WHO), about 5-15% of the world population is infected with influenza virus annually. In March 2009, with change in the pattern of occurrence of influenza in Mexico, influenza virus A (H1N1), a quadruple recombinant never seen before, was identified by analyzing samples of nasopharyngeal secretions from symptomatic American children, confirming the epidemiological link with the cases in Mexico (CDC / Atlanta, 2009) and months, with sustained transmission from person to person and involvement of various countries and nations, was sparked a new pandemic. OBJECTIVES - The objectives of this study were to describe the temporal evolution, characterize the patterns of morbidity and mortality in different periods and to identify factors associated with the occurrence and severity of deaths in different phases of pandemic Influenza A (H1N1) 2009 in CearÃ. METHODS - This study is a descriptive, retrospective study of cases reported and confirmed pandemic influenza (H1N1) 2009 in the state of CearÃ, in the years 2009 and 2010. RESULTS AND DISCUSSION - The pandemic occurred in three small waves, one at retention phase, characterized by mild, with rapid resolution. The second two waves, the mitigation phase, with more severe cases, higher rates of hospitalization, all patients who required intensive care (ICU) and all patients who died. 615 cases were reported, 144 of these were confirmed. 55.5% were female, 30% were mixed race, 72.5% of the cases had some serious comorbidity and 40 patients required hospitalization. Hospital mortality was 20%, and mortality in the ICU was 66%. Were significant for evolution to cure or death issues related to the demand for medical care, delay in initiation of antiviral therapy, obesity, low education, use of mechanical ventilation and be hospitalized in hospitals with specialized care. CONCLUSION - The data analysis of this study allowed in-depth knowledge about the pattern of morbidity and mortality caused by pandemic influenza A (H1N1) 2009 in the state of CearÃ. The study suggests that pandemic influenza A (H1N1) 2009 in this region of Brazil was magnitude lower compared to other states in other regions of the country with low incidence but high mortality rates in ICU patients.

Les profils de viabilité sur surface, de virus non enveloppés : murine minute virus (MVM), coxsackievirus B4 (CVB4), virus simien 40 (SV40), et de virus enveloppés : virus de grippe A (H1N1), et virus herpès simplex de type 1 (HSV-1), ainsi que la résistance à la chaleur et aux ultraviolets C (UVc) de ces virus ont été étudiés.Pour déterminer la viabilité de MVM, CVB4, H1N1 et HSV-1 sur surface, 50 µL de suspension virale ont été déposées sur des couvercles de boites de Pétri et séchés sous un flux d’air avant d’être récupérés et titrés sur des lignées cellulaires appropriées. Les virus enveloppés ont persisté moins de 5 jours alors que CVB4 et MVM restent infectieux pendant plusieurs semaines. Cependant, les cycles répétés de séchage et de remise en suspension ont eu un effet plus virucide sur CVB4 que sur H1N1 et HSV-1. Aucun effet des répétitions de ces cycles n’a été observé sur le titre infectieux du MVM. Quand il est exposé au séchage, les concentrations initiales d’albumine de sérum bovin, de sérum de veau fœtal et de chlorure de sodium, ont un impact sur la survie de CVB4. Dans un milieu riche en protéines, CVB4 a été plus facilement inactivé par le séchage, alors qu’en présence de chlorure de sodium le pouvoir virucide du séchage a été réduit. Ces résultats montrent que la résistance des virus vis-à-vis du séchage, n’est pas due à une hétérogénéité de populations virales, mais peut être influencée par la composition du milieu et la concentration des composants.Nous avons évalué la résistance thermique de MVM, CVB4, H1N1 et HSV-1 contenus dans des gouttelettes. Quatre microlitres de suspension virale ont été déposés sur une surface chauffée et exposés à des températures comprises entre 70 et 130°c pendant 0 à 90min, selon le virus, avant d’être titrés. Clairement, MVM a été plus résistant que H1N1, lui-même plus résistant que HSV-1 et CVB4. Pour la première fois, l’inactivation de particules virales contenues dans des gouttelettes exposées à des températures supérieures à 100°C a été étudiée. Il apparaît que le chauffage peut provoquer un effet plus rapidement virucide que décrit précédemment.La résistance aux UVc (254nm) de MVM, CVB4, H1N1, HSV-1 et SV40 contenus dans des gouttelettes a été évaluée. Les virus à ADN double brins (HSV-1 et SV40) restaient infectieux après une exposition à 60mJ/cm² d’UVc, tandis que les virus à ARN (H1N1 et CVB4) et un virus à ADN simple brin (MVM) ont été totalement inactivés par une exposition inférieure ou égale à 35mJ/cm² d’UVc. De plus l’effet des UVc combiné à la chaleur sur la viabilité de MVM a été déterminé. Le titre infectieux de MVM, contenu dans une gouttelette a été totalement inactivé après une exposition à 27mJ/cm² d’UVc. Le chauffage (20s à 100°C) a provoqué une réduction modérée du titre viral de MVM (-1.8 log10TCID50), alors que le chauffage suivi par une exposition à 17mJ/cm² d’UVc entraine une inactivation complète.En conclusion, nos études montrent que les virus peuvent persister pendant des jours voire des semaines sur une surface hydrophobe. Le profil de résistance des virus vis-à-vis du séchage, n’est pas dû à une hétérogénéité de populations virales, comme l’ont montré les résultats obtenus avec CVB4. De plus, dans la mesure où la composition du milieu joue un rôle dans la viabilité des virus exposés au séchage, la persistance des virus devrait être étudiée dans des milieux naturels plutôt que dans des milieux définis. L’impact de temps d’exposition courts à la chaleur sur les virus contenus dans de petits volumes de suspension a été déterminé. La résistance thermique de H1N1 jusqu’à 100°C, supérieure à celle d’HSV-1, un autre virus enveloppé, et à celle de CVB4 un virus non-enveloppé a été observée. Une inactivation virale efficace peut être obtenue en combinant une exposition aux UVc et à la chaleur comme le montrent les résultats obtenus avec MVM. / The pattern of viability of non-enveloped viruses, minute virus of mice (MVM), coxsackievirus B4 (CVB4), and simian virus 40 (SV40) and enveloped-viruses, influenza A virus (H1N1), and herpes simplex virus type 1 (HSV-1) onto surfaces and their resistance to heating and to ultraviolet C (UVc) exposure have been investigated. To determine the viability of MVM, CVB4, H1N1 and HSV1 on surface, fifty microliters of viral suspension were applied onto petri dish lids and dried under air flow of biosafety cabinet. The recovered viral preparations were titered on appropriate cell cultures. Enveloped viruses persisted for less than 5 days while CVB4 and MVM persisted for weeks. However, repetitive cycles of drying and resuspension had more virucidal effect on CVB4 than on H1N1 and HSV-1. No effect of these repetitive cycles on infectious titer of MVM was recorded. When exposed to drying, initial concentrations of bovine serum albumin, foetal calf and sodium chloride (NaCl) had an impact on the viability of CVB4. In a protein rich medium, CVB4 was more likely inactivated by drying whereas in presence of NaCl, the impact of drying was reduced. Thus, it appears that the resistance of viruses toward drying is not due to a heterogeneity of viral populations, but it can be influenced by media composition and components concentrations.Heat inactivation of viruses was reported, however, the thermal resistance of viruses in droplets has not been studied. We evaluated the pattern of heat resistance of MVM, CVB4, H1N1 and HSV1 contained in droplets. Four microliters droplets containing viruses were applied onto warmed surface obtained by using a self-made heating device. Viral suspensions were exposed to temperatures ranging from 70 to 130°C for 0 to 90 min depending on the virus, and then the recovered viral preparations were titered. Clearly, MVM was more resistant than H1N1 that was more resistant than HSV-1 and CVB4. For the first time, the inactivation of viral particles contained in drops exposed to temperatures higher than 100°C has been investigated. It appears that heating can have an unexpected faster virucidal effect than previously described. The resistance to ultraviolet C (UVc) (254nm) of MVM, CVB4, H1N1, HSV-1 and SV40 contained in droplets has been evaluated. Double-stranded DNA viruses (HSV-1 and SV40) were still infectious after exposure to 60 mJ/cm² UVc, while RNA viruses H1N1, CVB4 and single-stranded DNA virus MVM were fully inactivated when they were exposed to a dose equal to or lower than 35 mJ/cm² UVc. Moreover the effect of UVc (254 nm) combined with heating onto the viability of MVM was determined. The infectious level of MVM suspension droplets applied onto petri dish lids was fully inactivated when exposed to 27 mJ/cm² UVc. Heating (100°C for 20s) provoked a moderate reduction of infectious level (-1.8 log10TCID50) of MVM, whereas heating followed by UVc exposure (17 mJ/cm²) resulted in a full inactivation.In conclusion, our studies show that viruses can persist for days or even weeks on dry hydrophobic surfaces. The pattern of resistance of viruses toward drying is not due to a heterogeneity of viral population as shown by results obtained with CVB4. In so far as media composition play a role in the viability of viruses exposed to drying, the persistence of viruses in natural media (clinical or environmental), instead of defined media, should be investigated. The impact of short time exposure to heat onto the infectivity of viruses contained in a small volume of suspension has been determined. The thermal resistance of H1N1 up to 100°C, higher than the one of HSV1 another enveloped virus, and CVB4 a non-enveloped virus has been observed. An efficient viral inactivation can be obtained by combining UVc exposure and heating as shown by results obtained with MVM.

學校停課在世界各國的流感大流行應對方案中常被列為一項社區緩疫措施，而這項措施亦在2009年H1N1流感大流行中被廣泛地使用。然而，這項緩疫措施經常被質疑是否恰當，原因是因為停課會對教育構成重大的影響，而且過往的流行病學硏究亦表示這項緩疫措施不一定有效。本論文硏究學校停課對2009年H1N1流感大流行在香港首5個月疫情中降低大流行流感傳播的效能。 / 在香港，在該大流行流感病毒於2009年4月在美國被發現後，香港政府實施了控疫措施(containment phase measures)，並開始對該流感大流行進行監測。為了判定大流行是否已在香港內蔓延，衛生防護中心設定了一個報告準則來讓本地醫生報告疑似大流行流感感染個案，並為每個懷疑個案作確診測試及為每個確診個案追溯感染源頭。當大流行流感在6月開始在香港內蔓延時，香港政府實施了緩疫措施(mitigation phase measures)。在緩疫措施底下，帶有流感病症的病人求診於指定流感診所和公共醫院急症室會被測試是否感染大流行流感，而停課措施亦在此時開始實行去減低大流行流感的傳播。停課措施一直維持至7月直至暑假開始，並經修改後於9月開學時繼續實行。在9月，鑑於已不再需要對流感大流行進行監測，對懷疑感染個案進行確診測試的政策止於該月下旬。確診個案中記錄了的病人資料，與及由學校停課和暑假所引起的學期變化，為這課題提供了一個理想硏究的機會。 / 在2009年的5月至9月，一共確診了27,687宗大流行流感個案。在確診個案中，所有個案都記錄了確診者的年歲和確診日期，而88%確診者提供了一個可定位的住宅地址。為了觀察學校停課的緩疫效果，本硏究定義了5個社會經濟年齡級別(socio-economic age classes) (當中包括有小學生和中學生)，並繪製了年齡級別與地域特定的疫情曲線(age-class-and-district-specific epidemic curves)。所有的疫情曲線在大流行流感在6月開始在香港蔓延後均穩步上升，而在屬於小學生和中學生的疫情曲線中能看到一個不尋常的上升出現在9月新學年開始時，意味著中小學生在學校的活動提升了大流行流感在他們之間的傳播。 / 先前，學校停課對減低2009年H1N1流感大流行在香港的傳播已被Wu et. al (2010a)進行了調查。透過使用一個具年齡結構的SIR模型(age-structured SIR model)來分析收集至8月27日的監測數據，該硏究表示流感大流行的傳播在暑假開始時減低了25%。在這研究中，我應用了Wu et. al (2010a)的方法來分析整個監測期間所收集的數據。在發現到該數學模型不能準確地擬合附加的監測數據後，我在該模型添加了兩個傳播特徵(當中包含兒童和成人之間的傳染在學校停課期間增加)去更準確地代表現實中的疫情。我的硏究顯示，學校停課雖然降低了兒童的感染率，但卻增加了成年人的感染率，令整體傳播在暑假開始時只減低了7.6%。這硏究結果表示，在將來的流感大流行中，封閉學校不大可能延遲流感大流行疫情至一個可令疫苗產生作用的程度，而且封閉學校可能會增加成人的感染率，從而有可能導致社會運作出現更混亂的情況。 / School closure is often included in national pandemic influenza response plans as a community mitigation measure and it was widely applied in Pandemic (H1N1) 2009. However, the appropriateness of this intervention is often questioned, as school closure causes major disruption to the education system and past epidemiological studies reveal this intervention is not necessarily effective. The present thesis evaluates the effect of school closure in mitigating transmission of Pandemic (H1N1) 2009 in Hong Kong in the initial 5 months of the pandemic. / In Hong Kong, following identification of the pandemic virus in US in April 2009, the government implemented containment phase measures and began surveillance on the pandemic. The Centre for Health Protection established a reporting criteria for doctors to report suspected cases of pandemic infection for laboratory confirmation, and the source of infection of confirmed cases was traced to determine if the pandemic was spreading locally. When local transmission of the pandemic began in June, the government began mitigation phase measures, in which patients with influenza-like- illness seeking treatment at designated flu clinics and public hospital emergency departments were tested for pandemic infection, and school closure was implemented for pandemic mitigation. The school closure policy lasted until summer holiday commenced in July, and was revised and continued in September when the new school season started. At the end of September, in view of pandemic surveillance was no longer useful, laboratory testing for suspected pandemic cases was halted. Patient demographic data collected from confirmed pandemic cases, together with temporal changes in school session induced by school closure and summer holiday, provided an ideal opportunity for investigation. / From May through September 2009, a total of 27,687 pandemic cases were confirmed, in which the age and confirmation date were recorded in all cases, and 88% provided a locatable residential address. To visualise the mitigative effect of school closure, 5 socio-economic age classes (which include primary and secondary school-aged children) were defined, and age-class-and-district-specific epidemic curves were constructed. All epidemic curves rose steadily after local transmission began in June, and an unusual upsurge in the epidemic curve of primary and secondary school-aged children is observed when schools resumed session in September, suggesting school session facilitated transmission amongst them. / Previously, the effect of school closure in mitigating Pandemic (H1N1) 2009 transmission in Hong Kong was investigated in Wu et al. (2010a). By analysing surveillance data collected as of 27 August with an age-structured susceptible- infectious-recovered (SIR) model, the study reported transmission was reduced by 25% when summer holiday commenced. In this study, I adapted the methodology in Wu et al. (2010a) to analyse data collected in the entire surveillance period. Upon observing the model fitted poorly to the additional data, I added 2 transmission features to the model (which include increased transmission between children and adults during school closure) to better represent the epidemic in reality. My analysis revealed that while school closure reduced incidence in children, it increased incidence in adults, leading to a reduction in overall transmission by only 7.6% when summer holiday started. The findings of this study suggest that school closure in a future influenza pandemic is unlikely to be able to delay the pandemic for vaccine to arrive in time, and that implementing this intervention may increase incidence in adults, which may lead to causing more disruption on the functioning of society. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Chau, Kwan Long. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 148-154). / Abstracts also in Chinese. / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Influenza --- p.2 / Chapter 1.2 --- Public health response to pandemic influenza & School closure --- p.8 / Chapter 1.3 --- Pandemic (H1N1) 2009 --- p.13 / Chapter 1.4 --- Hong Kongs response to Pandemic (H1N1) 2009 --- p.17 / Chapter 1.5 --- Data and Research Objective --- p.24 / Chapter Chapter 2 --- Descriptive and Exploratory Analysis of Surveillance Data --- p.31 / Chapter 2.1 --- Introduction --- p.31 / Chapter 2.2 --- Methodology --- p.36 / Chapter 2.3 --- Results --- p.40 / Chapter 2.4 --- Discussion --- p.57 / Chapter Chapter 3 --- Evaluating the effect of School Closure by Modelling --- p.62 / Chapter 3.1 --- Introduction --- p.62 / Chapter 3.2 --- Methodology --- p.90 / Chapter 3.3 --- Results --- p.98 / Chapter 3.4 --- Discussion --- p.105 / Chapter Chapter 4 --- Discussion --- p.108 / Chapter 4.1 --- Study Findings --- p.108 / Chapter 4.2 --- Study Limitations --- p.109 / Chapter 4.3 --- Comments on using school closure in future influenza pandemics --- p.111 / Appendices --- p.116 / Bibliography --- p.148

Objetivos: Avaliar a imunogenicidade e segurança da vacina anti-influenza A/H1N1 2009 em pacientes com dermatomiosite juvenil (DMJ) comparados com controles saudáveis e a possível associação entre taxas de soroconversão com dados demográficos, enzimas musculares, escores da DMJ, linfopenia e tratamento nos pacientes com DMJ atendidos em dois serviços de Reumatologia Pediátrica. Métodos: Trinta pacientes com DMJ entre 9 e 21 anos e 81 controles saudáveis foram imunizados com a vacina anti-influenza A H1N1/2009 sem adjuvante. Todos foram avaliados pré e 21 dias após a vacinação. As taxas de soroproteção e soroconversão, a média geométrica dos títulos de anticorpos (MGT) e o fator de aumento (FA) na MGT foram calculados. Foram analisados os eventos adversos (EAs), assim como: enzimas musculares, instrumentos de força muscular, presença de linfopenia e tratamento atual da DMJ. Resultados: Pacientes com DMJ e controles foram comparáveis em relação à mediana de idade atual [15,5 (9- 21) vs. 15 (9-21) anos, p=0,511] e frequência do sexo feminino (63% vs. 51%, p=0,286). A mediana do tempo de duração da DMJ foi de 5,5 (2-17) anos. Após a imunização, as taxas de soroconversão foram significantemente menores em pacientes com DMJ comparados com controles saudáveis (86,7% vs. 97,5%, p=0,044), enquanto soroproteção (p=0,121), MGT (p=0,992) e FA na MGT (p=0,827) foram semelhantes entre os grupos. As avaliações clínicas e laboratoriais na DMJ mostraram que as medianas dos escores de avaliação da atividade doença e enzimas musculares permaneceram estáveis no período do estudo (p > 0,05). Uma alta frequência de curso clínico crônico da doença foi observada em pacientes que não apresentaram soroconversão em comparação aos pacientes soroconvertidos (100% vs. 27%, p=0,012). Em relação à influência do tratamento, baixas taxas de soroconversão foram observadas em pacientes em uso de metotrexate (100% vs. 38%, p=0,036) e associação de prednisona, metotrexate e ciclosporina (50% vs. 4%, p=0,039). EAs locais e/ou sistêmicos foram leves e similares entre pacientes e controles (p > 0,05). Conclusão: Este foi o primeiro estudo que avaliou a vacina anti-influenza A H1N1/2009 na DMJ, identificando que o curso crônico da doença e a terapia imunossupressora são fatores que podem prejudicar a resposta humoral nos pacientes. Uma única dose da vacina foi soroprotetora nos pacientes avaliados, sem evidências de efeitos deletérios na atividade da doença / Objectives: To assess the immunogenicity and safety of influenza A H1N1/2009 vaccine in juvenile dermatomyositis (JDM) patients compared to age-matched controls and the possible association of seroconversion rates whith demographic, muscle enzymes, JDM scores, lymphopenia and treatment in JDM patients routinely followed at two Pediatric Rheumatology Units. Methods: Thirty JDM patients between 9 and 21 years old and 81 healthy age-matched controls were vaccinated with non-adjuvanted influenza A H1N1/2009 vaccine. All participants were evaluated pre- and 21 days postvaccination. Seroconversion and seroprotection rates, geometric mean titres (GMT) and factor increase (FI) in GMT were assessed. Adverse events, as well as muscle enzymes, JDM scores, lymphopenia and current treatment in JDM were also evaluated. Results: JDM patients and healthy controls had similar median of current age [15.5 (9-21) vs. 15 (9-21) years, p=0.511] and frequencies of female gender (63% vs. 51%, p=0.286). The median disease duration of JDM was 5.5 (2-17) years. After immunization, seroconversion rate was significantly lower in JDM patients compared to age-matched controls (86.7 vs. 97.5%, p=0.044), whereas seroprotection (p=0.121), GMT (p=0.992) and FI in GMT (p=0.827) were similar in both groups. Clinical and laboratorial evaluations revealed that JDM scores and muscle enzymes remained stable throughout the study (p > 0.05). A higher frequency of chronic course was observed in non-seroconvert compared to seroconverted (100% vs. 27%, p=0.012). Regarding treatment, a lower rate of seroconversion was observed in patients treated with methotrexate (100% vs. 38%, p=0.036) and in those with a combination of prednisone, methotrexate and cyclosporine (50% vs. 4%, p=0.039). Local and systemic adverse events were mild and similar in JDM patients and controls (p > 0.05). Conclusions: This was the first study that evaluated the influenza A H1N1/2009 vaccine in JDM, identified that chronic course and immunosuppressive therapy were factors hampering immune response in patients. A single dose of non-adjuvanted influenza A/H1N1 2009 vaccine was seroprotective in assessed patients with no evident deleterious effect in disease itself

Objetivos: Avaliar a imunogenicidade e segurança da vacina anti-influenza A/H1N1 2009 em pacientes com dermatomiosite juvenil (DMJ) comparados com controles saudáveis e a possível associação entre taxas de soroconversão com dados demográficos, enzimas musculares, escores da DMJ, linfopenia e tratamento nos pacientes com DMJ atendidos em dois serviços de Reumatologia Pediátrica. Métodos: Trinta pacientes com DMJ entre 9 e 21 anos e 81 controles saudáveis foram imunizados com a vacina anti-influenza A H1N1/2009 sem adjuvante. Todos foram avaliados pré e 21 dias após a vacinação. As taxas de soroproteção e soroconversão, a média geométrica dos títulos de anticorpos (MGT) e o fator de aumento (FA) na MGT foram calculados. Foram analisados os eventos adversos (EAs), assim como: enzimas musculares, instrumentos de força muscular, presença de linfopenia e tratamento atual da DMJ. Resultados: Pacientes com DMJ e controles foram comparáveis em relação à mediana de idade atual [15,5 (9- 21) vs. 15 (9-21) anos, p=0,511] e frequência do sexo feminino (63% vs. 51%, p=0,286). A mediana do tempo de duração da DMJ foi de 5,5 (2-17) anos. Após a imunização, as taxas de soroconversão foram significantemente menores em pacientes com DMJ comparados com controles saudáveis (86,7% vs. 97,5%, p=0,044), enquanto soroproteção (p=0,121), MGT (p=0,992) e FA na MGT (p=0,827) foram semelhantes entre os grupos. As avaliações clínicas e laboratoriais na DMJ mostraram que as medianas dos escores de avaliação da atividade doença e enzimas musculares permaneceram estáveis no período do estudo (p > 0,05). Uma alta frequência de curso clínico crônico da doença foi observada em pacientes que não apresentaram soroconversão em comparação aos pacientes soroconvertidos (100% vs. 27%, p=0,012). Em relação à influência do tratamento, baixas taxas de soroconversão foram observadas em pacientes em uso de metotrexate (100% vs. 38%, p=0,036) e associação de prednisona, metotrexate e ciclosporina (50% vs. 4%, p=0,039). EAs locais e/ou sistêmicos foram leves e similares entre pacientes e controles (p > 0,05). Conclusão: Este foi o primeiro estudo que avaliou a vacina anti-influenza A H1N1/2009 na DMJ, identificando que o curso crônico da doença e a terapia imunossupressora são fatores que podem prejudicar a resposta humoral nos pacientes. Uma única dose da vacina foi soroprotetora nos pacientes avaliados, sem evidências de efeitos deletérios na atividade da doença / Objectives: To assess the immunogenicity and safety of influenza A H1N1/2009 vaccine in juvenile dermatomyositis (JDM) patients compared to age-matched controls and the possible association of seroconversion rates whith demographic, muscle enzymes, JDM scores, lymphopenia and treatment in JDM patients routinely followed at two Pediatric Rheumatology Units. Methods: Thirty JDM patients between 9 and 21 years old and 81 healthy age-matched controls were vaccinated with non-adjuvanted influenza A H1N1/2009 vaccine. All participants were evaluated pre- and 21 days postvaccination. Seroconversion and seroprotection rates, geometric mean titres (GMT) and factor increase (FI) in GMT were assessed. Adverse events, as well as muscle enzymes, JDM scores, lymphopenia and current treatment in JDM were also evaluated. Results: JDM patients and healthy controls had similar median of current age [15.5 (9-21) vs. 15 (9-21) years, p=0.511] and frequencies of female gender (63% vs. 51%, p=0.286). The median disease duration of JDM was 5.5 (2-17) years. After immunization, seroconversion rate was significantly lower in JDM patients compared to age-matched controls (86.7 vs. 97.5%, p=0.044), whereas seroprotection (p=0.121), GMT (p=0.992) and FI in GMT (p=0.827) were similar in both groups. Clinical and laboratorial evaluations revealed that JDM scores and muscle enzymes remained stable throughout the study (p > 0.05). A higher frequency of chronic course was observed in non-seroconvert compared to seroconverted (100% vs. 27%, p=0.012). Regarding treatment, a lower rate of seroconversion was observed in patients treated with methotrexate (100% vs. 38%, p=0.036) and in those with a combination of prednisone, methotrexate and cyclosporine (50% vs. 4%, p=0.039). Local and systemic adverse events were mild and similar in JDM patients and controls (p > 0.05). Conclusions: This was the first study that evaluated the influenza A H1N1/2009 vaccine in JDM, identified that chronic course and immunosuppressive therapy were factors hampering immune response in patients. A single dose of non-adjuvanted influenza A/H1N1 2009 vaccine was seroprotective in assessed patients with no evident deleterious effect in disease itself

Os pacientes com doenças reumáticas crônicas exibem um risco aumentado de contrair infecções. Consequentemente, sua vacinação é indispensável. Há relatos da produção de anticorpos antifosfolípides e tromboses após infecções e vacinação nesta população, exceto em síndrome antifosfolípide (SAF) primária. O objetivo principal deste estudo foi avaliar a curto e longo prazos um painel de anticorpos antifosfolípides após a vacinação contra influenza A/H1N1 (sem adjuvante) em SAF primária e controles saudáveis. Quarenta e cinco pacientes com SAF primária e 33 controles saudáveis foram imunizados e prospectivamente avaliados antes da vacinação e 3 semanas e 6 meses após a vacinação. Os anticorpos antifosfolípides foram determinados por ensaio imunoenzimático (ELISA) e incluíram os anticorpos IgG e IgM a seguir: anticardiolipina (aCL), anti-beta2glicoproteína I (anti-beta2GPI), anti-anexina V, anti-fosfatidilserina e anti-protrombina. O anticorpo anti-Sm foi igualmente determinado por ELISA e o anti-DNA dupla hélice, por imunofluorescência indireta. Avaliamos clinicamente à ocorrência de tromboses arterial e venosa. A frequência pré-vacinação de pelo menos um anticorpo antifosfolípide foi significativamente maior nos pacientes com SAF primária comparados aos controles (58% vs 24%, p = 0,0052). A frequência global de anticorpos antifosfolípides pré-vacinação e 03 semanas e 06 meses após a vacinação permaneceu inalterada tanto em pacientes (p = 0,89) como em controles (p = 0,83). A frequência de cada anticorpo específico nos dois grupos permaneceu estável nas três avaliações (p > 0,05). A frequência de cada anticorpo mantevese invariável nos pacientes tratados com cloroquina (p > 0,05). Em 3 semanas, 2 pacientes com SAF primária deselvolveram um anticorpo antifosfolípide novo porém transitório (aCL IgG e IgM), enquanto que em 6 meses novos anticorpos foram observados em 6 pacientes e nenhum apresentou altos títulos. Anti-Sm e anti-DNA dupla hélice foram negativos e nenhuma nova trombose arterial ou venosa foi observada durante o estudo. Este foi o primeiro estudo a demonstrar que a vacina contra influenza pandêmica em pacientes com SAF primária não induz tromboses e uma produção significante de anticorpos antifosfolípides a curto e longo prazos. (ClinicalTrials.gov, #NCT01151644). / Chronic rheumatic disease patients exhibit an increased risk for infections. Therefore, vaccination is imperative. Antiphospholipid antibodies (aPL) and thrombosis triggering after infections and vaccination in this population were reported, except for primary antiphospholipd syndrome (PAPS). Study\'s main objective was short and long-term evaluation of a panel of antiphospholipid autoantibodies following pandemic influenza A/H1N1 non-adjuvant vaccine in primary antiphospholipid syndrome patients and healthy controls. Forty-five PAPS and 33 healthy controls were immunized with A/H1N1 pandemic influenza vaccine. They were prospectively assessed at pre-vaccination, 3 weeks and 6 months after vaccination. aPL autoantibodies were determined by an enzyme-linked immunosorbent assay (ELISA) and included IgG/IgM: anticardiolipin (aCL), anti-beta2GPI; anti-annexin V, anti-phosphatidyl serine and antiprothrombin antibodies. Anti-Sm was determined by ELISA and anti-dsDNA by indirect immunfluorescence. Arterial and venous thrombosis were also clinically assessed. Pre-vaccination frequency of at least one aPL antibody was significantly higher in PAPS patients versus controls (58% vs. 24%, p=0.0052). The overall frequencies of aPL antibody at pre-vaccination, 3 weeks and 6 months after immunization remained unchanged in patients (p=0.89) and controls (p=0.83). The frequency of each antibody specificity for patients and controls remained stable in the three evaluated period (p > 0.05). The frequency of each antibody kept invariable in PAPS patients under chloroquine treatment (p > 0.05). At 3 weeks, 2 PAPS patients developed a new but transient aPL antibody (aCL IgG and IgM), whereas at 6 months new aPL antibodies were observed in 6 PAPS patients and none had high titer. Anti-Sm and anti-dsDNA autoantibodies were uniformly negative and no new arterial or venous thrombosis were observed throughout the study. This was the first study to demonstrate that pandemic influenza vaccine in PAPS patients does not trigger short and long-term thrombosis or a significant production of aPL related antibodies. (ClinicalTrials.gov, #NCT01151644)

Estudos recentes têm apresentado resultados in vitro satisfatórios em pacientes com Imunodeficiência Comum Variável (ICV) que receberam vacinas contra tétano, influenza e meningococo. No entanto, existem poucos ensaios clínicos que avaliem a resposta clínica e laboratorial após a exposição a antígenos específicos. O presente estudo tem como objetivo avaliar a resposta clínica à imunização contra antígenos protéicos e polissacarídicos (influenza, H1N1 e pneumococo) em pacientes com diagnóstico de ICV seguidos no ambulatório de Imunodeficiências Primárias do Serviço de Imunologia Clínica e Alergia do HC-FMUSP. O diagnóstico dos pacientes foi estabelecido de acordo com os critérios da OMS / PAGID / ESID. Um grupo de 37 pacientes foi vacinado contra a influenza A (H2N3), gripe H1N1 e pneumococo e outro grupo com 16 pacientes, não foi vacinado. A avaliação clínica foi realizada através da aplicação de um score com avaliação dos seguintes parâmetros clínicos: pneumonia, sinusite, otite média, infecções de vias aéreas superiores (IVAS), amigdalites, diarréia, bronquiectasias, hospitalizações, uso de antibióticos, uso de antibióticos profiláticos, sepse e meningite. O score foi aplicado durante os 12 meses que precederam a vacinação e 12 meses posteriores à administração das vacinas. O mesmo score foi aplicado ao grupo controle, com os pacientes que não foram vacinados. A determinação da IgG contra os sorotipos do pneumococo foi feita por ELISA. A determinação da IgG específica H1N1 foi feita por hemaglutinação indireta, enquanto que a dosagem da IgG específica para influenza, por ELISA, utilizando o kit comercial RIDASCREEN ® Influenza. O grupo de pacientes vacinados incluiu 37 pacientes (51% mulheres), com idade entre 20 e 78 anos (mediana= 33 anos). Observou-se uma mediana de 7 anos de atraso no diagnóstico de ICV. A mediana de idade do grupo de pacientes (n=16, 37,5% mulheres) que não receberam a vacina foi de 41 anos e a mediana de atraso no diagnóstico foi de 8 anos. Observamos que as infecções de vias aéreas superiores (IVAS), sinusites e pneumonias foram as manifestações mais freqüentes no grupo controle. IVAS seguida por pneumonia e sinusite foram as manifestações infecciosas mais freqüentes em mulheres (80%, 78% e 55%, respectivamente). Entretanto, em homens observamos IVAS seguido por sinusite e pneumonia (78%, 65% e 35%, respectivamente). Observou-se redução significativa no score relativo ao número de infecções respiratórias superiores, sinusites e pneumonias um ano após a administração das vacinas (p <0,001). Os dados foram comparados com pacientes ICV não vacinados e neste grupo não houve diferença entre os scores dos dois períodos de 12 meses . Após a vacinação, observou-se uma tendência a aumento no título de anticorpos específicos para a H2N3, mas sem resultado significativo. Em relação aos resultados obtidos com as sorologias para o H1N1 e o pneumococo, não se observou resposta após a vacinação. Concluindo, houve redução do número de infecções, principalmente das IVAS, sinusites e pneumonias em pacientes com ICV após a vacinação contra a influenza, H1N1 e pneumococo. Embora não tenhamos encontrado correlação entre a redução do número de infecções e os títulos de anticorpos específicos para as vacinas testadas, a melhora clínica observada nos pacientes com ICV reforça o benefício da vacinação / Recent studies have shown satisfactory in vitro results in patients with CVID who received immunization against tetanus, influenza and meningococcus. However, there are only a few studies that evaluate the clinical and laboratory response after exposure to specific antigens in these patients. This study aims to evaluate the clinical response to immunization with protein and polysaccharide antigens (influenza, H1N1 and pneumococcus) in CVID patients followed at the Primary Immunodeficiency outpatient clinic of the Division of Clinical Immunology and Allergy, Hospital das Clínicas, FMUSP. CVID patients were diagnosed according the WHO/PAGID/ ESID criteria. Thirty-seven patients were immunized against influenza (H2N3), H1N1 and pneumococcal polysaccharide vaccine while another group with 16 CVID patients were not vaccinated. Clinical evaluation was performed through a score with assessment of the following parameters: pneumonia, sinusitis, otitis media, upper respiratory infections (URI), tonsillitis, diarrhea, bronchiectasis, hospitalizations, use of antibiotic therapy, and use of prophylactic antibiotics, sepsis and meningitis. The score was applied during the 12 months prior to immunization and one year after the administration of vaccines. The same score was applied to the group of CVID patients who weren´t immunized. Determination of IgG antibodies to pneumococcal serotypes was made by ELISA. H1N1-specific IgG was detected by indirect hemagglutination while the determination of influenzaspecific IgG was performed by ELISA, using the RIDASCREEN ® Influenza kit. The group of patients who were vaccinated included 37 patients (51% women), aged 20 to 78 years (mean 33 years). This group presented a median delay in the diagnosis of 7 years. The control group consisted of 16 patients (37.5% females) who were not immunized. Their median age was 41 years and the median delay in the diagnosis was 8 years. URI followed by pneumonia and sinusitis were the most frequent infections in women (80%, 78% and 55% respectively). However in men, URI followed by sinusitis and pneumonia were the most frequent (78%, 65% and 35% respectively). We observed a significant reduction in the score of URI, sinusitis and pneumonias in the year post administration of the vaccines (p <0.001). Conversely, there was no difference in the infections pre and post supposed vaccination scores in the group of CVID patients who were not immunized. There was no significant change in specific antibody titers to influenza and pneumococcus after vaccination. Regarding H1N1, there was no statistically significant production of antibodies to H1N1, although we observed a slight non-durable increase in antibody titers. In conclusion, there was a reduction in the number of infections, mainly sinusitis, URIs and pneumonias in patients with CVID vaccinated against influenza, H1N1 and pneumococcus. While we found no correlation between the reduction in the number of infections and specific antibody titers for the vaccines administered, the clinical improvement observed in CVID patients reinforces the benefit of vaccination

Introdução: A vacinação contra a influenza pandêmica A/H1N1 resultou em soroproteção em mais de 85% dos indivíduos saudáveis. Entretanto, dados em pacientes com artrite reumatoide (AR) são escassos. Objetivos: O objetivo deste estudo é avaliar a imunogenicidade e a segurança em curto prazo da vacina contra influenza pandêmica A/H1N1 em pacientes com AR e a influência da atividade da doença e da medicação nesta resposta. Métodos: Trezentos e quarenta pacientes adultos com AR em seguimento e tratamento regular e 234 controles saudáveis foram examinados antes e 21 dias após receber uma dose da vacina sem adjuvante contra influenza A/California/7/2009. A atividade da doença (DAS28), o tratamento em uso e os títulos de anticorpos também foram avaliados. As taxas de soroproteção (títulos de anticorpos >= 1:40) e soroconversão (percentagem de pacientes com aumento de título de anticorpos maior ou igual a 4, se o título pré- vacinal fosse maior ou igual a 1:10; ou título pós-vacinal de pelo menos 1:40, se o título pré-vacinal era menor que 1:10), as médias geométricas dos títulos (MGT) e o fator de incremento das médias geométricas (FI-MGT) foram calculados. Os eventos adversos foram também registrados. Resultados: Os pacientes com AR e os controles tinham taxas pré-vacinais de soroproteção (10,8% vs. 11,5%) e MGT (8,0 vs. 9,3) comparáveis (p>0,05). Após a vacinação, foi observada redução significativa na resposta dos pacientes com AR versus controles (p<0,001) em todos os desfechos sorológicos: taxas de soroproteção (60,0 vs. 82,9%) e soroconversão (53,2% vs. 76,9%), MGT (57,5 vs. 122,9) e FI-MGT (7,2 vs. 13,2). A atividade de doença não prejudicou a soroproteção ou a soroconversão e se manteve estável em 97,4% dos pacientes. O metotrexato e o abatacepte foram associados à redução da resposta vacinal. A vacinação foi bem tolerada, com poucos efeitos adversos. Conclusão: Os dados confirmaram tanto a segurança em curto prazo como, diferente da maioria dos trabalhos com influenza sazonal, a redução da soroproteção em pacientes com AR, não relacionada à atividade de doença e à maioria das medicações em uso (com exceção do metotrexato e do abatacepte). A extrapolação da resposta imunológica de uma vacina para outra pode não ser possível e estratégias específicas de imunização (possivelmente em duas doses) podem ser necessárias / Background: Pandemic influenza A/H1N1 vaccination yielded seroprotection in more than 85% of healthy individuals. However, similar data are scarce in rheumatoid arthritis (RA) patients. Objectives: The objective of this study is to evaluate the immunogenicity and the short-term safety of anti- pandemic influenza A/H1N1 vaccine in RA patients, and the influence of disease activity and medication to the response. Methods: Three hundred and forty adult RA patients in regular follow-up and treatment, and 234 healthy controls were assessed before and 21 days after adjuvant-free influenza A/California/7/2009 vaccine. Disease activity (DAS28), current treatment and anti-pandemic influenza A/H1N1 antibody titres were also evaluated. Seroprotection (antibody titre >=1:40) and seroconversion (the percentage of patients with a fourfold or greater increase in antibody titre, if prevaccination titre was 1:10 or greater, or a postvaccination titre of 1:40 or greater, if prevaccination titre was less than 1:10) rates, geometric mean titres (GMT) and factor increase in geometric mean titre (FI-GMT) were calculated and adverse events registered. Results: RA patients and controls showed similar (p>0.05) prevaccination seroprotection (10.8% vs. 11.5%) and GMT (8.0 vs. 9.3). After vaccination a significant reduction (p<0.001) was observed in all endpoints in RA patients versus controls: seroprotection (60.0 vs. 82.9%; p<0.0001) and seroconversion (53.2% vs. 76.9%) rates, GMT (57.5 vs. 122.9) and FI-GMT (7.2 vs. 13.2). Disease activity did not preclude seroprotection or seroconversion and remained unchanged in 97.4% of patients. Methotrexate and abatacept were associated with reduced responses. Vaccination was well tolerated with minimal adverse events. Conclusions: The data confirmed both short-term anti-pandemic A/H1N1 vaccine safety and, different from most studies with seasonal influenza, reduced seroprotection in RA patients, unrelated to disease activity and to most medications (except methotrexate and abatacept). Extrapolation of xii immune responses from one vaccine to another may therefore not be possible and specific immunization strategies (possibly booster) may be needed

Introdução: A vacinação contra a influenza pandêmica A/H1N1 resultou em soroproteção em mais de 85% dos indivíduos saudáveis. Entretanto, dados em pacientes com artrite reumatoide (AR) são escassos. Objetivos: O objetivo deste estudo é avaliar a imunogenicidade e a segurança em curto prazo da vacina contra influenza pandêmica A/H1N1 em pacientes com AR e a influência da atividade da doença e da medicação nesta resposta. Métodos: Trezentos e quarenta pacientes adultos com AR em seguimento e tratamento regular e 234 controles saudáveis foram examinados antes e 21 dias após receber uma dose da vacina sem adjuvante contra influenza A/California/7/2009. A atividade da doença (DAS28), o tratamento em uso e os títulos de anticorpos também foram avaliados. As taxas de soroproteção (títulos de anticorpos >= 1:40) e soroconversão (percentagem de pacientes com aumento de título de anticorpos maior ou igual a 4, se o título pré- vacinal fosse maior ou igual a 1:10; ou título pós-vacinal de pelo menos 1:40, se o título pré-vacinal era menor que 1:10), as médias geométricas dos títulos (MGT) e o fator de incremento das médias geométricas (FI-MGT) foram calculados. Os eventos adversos foram também registrados. Resultados: Os pacientes com AR e os controles tinham taxas pré-vacinais de soroproteção (10,8% vs. 11,5%) e MGT (8,0 vs. 9,3) comparáveis (p>0,05). Após a vacinação, foi observada redução significativa na resposta dos pacientes com AR versus controles (p<0,001) em todos os desfechos sorológicos: taxas de soroproteção (60,0 vs. 82,9%) e soroconversão (53,2% vs. 76,9%), MGT (57,5 vs. 122,9) e FI-MGT (7,2 vs. 13,2). A atividade de doença não prejudicou a soroproteção ou a soroconversão e se manteve estável em 97,4% dos pacientes. O metotrexato e o abatacepte foram associados à redução da resposta vacinal. A vacinação foi bem tolerada, com poucos efeitos adversos. Conclusão: Os dados confirmaram tanto a segurança em curto prazo como, diferente da maioria dos trabalhos com influenza sazonal, a redução da soroproteção em pacientes com AR, não relacionada à atividade de doença e à maioria das medicações em uso (com exceção do metotrexato e do abatacepte). A extrapolação da resposta imunológica de uma vacina para outra pode não ser possível e estratégias específicas de imunização (possivelmente em duas doses) podem ser necessárias / Background: Pandemic influenza A/H1N1 vaccination yielded seroprotection in more than 85% of healthy individuals. However, similar data are scarce in rheumatoid arthritis (RA) patients. Objectives: The objective of this study is to evaluate the immunogenicity and the short-term safety of anti- pandemic influenza A/H1N1 vaccine in RA patients, and the influence of disease activity and medication to the response. Methods: Three hundred and forty adult RA patients in regular follow-up and treatment, and 234 healthy controls were assessed before and 21 days after adjuvant-free influenza A/California/7/2009 vaccine. Disease activity (DAS28), current treatment and anti-pandemic influenza A/H1N1 antibody titres were also evaluated. Seroprotection (antibody titre >=1:40) and seroconversion (the percentage of patients with a fourfold or greater increase in antibody titre, if prevaccination titre was 1:10 or greater, or a postvaccination titre of 1:40 or greater, if prevaccination titre was less than 1:10) rates, geometric mean titres (GMT) and factor increase in geometric mean titre (FI-GMT) were calculated and adverse events registered. Results: RA patients and controls showed similar (p>0.05) prevaccination seroprotection (10.8% vs. 11.5%) and GMT (8.0 vs. 9.3). After vaccination a significant reduction (p<0.001) was observed in all endpoints in RA patients versus controls: seroprotection (60.0 vs. 82.9%; p<0.0001) and seroconversion (53.2% vs. 76.9%) rates, GMT (57.5 vs. 122.9) and FI-GMT (7.2 vs. 13.2). Disease activity did not preclude seroprotection or seroconversion and remained unchanged in 97.4% of patients. Methotrexate and abatacept were associated with reduced responses. Vaccination was well tolerated with minimal adverse events. Conclusions: The data confirmed both short-term anti-pandemic A/H1N1 vaccine safety and, different from most studies with seasonal influenza, reduced seroprotection in RA patients, unrelated to disease activity and to most medications (except methotrexate and abatacept). Extrapolation of xii immune responses from one vaccine to another may therefore not be possible and specific immunization strategies (possibly booster) may be needed

Os pacientes com doenças reumáticas crônicas exibem um risco aumentado de contrair infecções. Consequentemente, sua vacinação é indispensável. Há relatos da produção de anticorpos antifosfolípides e tromboses após infecções e vacinação nesta população, exceto em síndrome antifosfolípide (SAF) primária. O objetivo principal deste estudo foi avaliar a curto e longo prazos um painel de anticorpos antifosfolípides após a vacinação contra influenza A/H1N1 (sem adjuvante) em SAF primária e controles saudáveis. Quarenta e cinco pacientes com SAF primária e 33 controles saudáveis foram imunizados e prospectivamente avaliados antes da vacinação e 3 semanas e 6 meses após a vacinação. Os anticorpos antifosfolípides foram determinados por ensaio imunoenzimático (ELISA) e incluíram os anticorpos IgG e IgM a seguir: anticardiolipina (aCL), anti-beta2glicoproteína I (anti-beta2GPI), anti-anexina V, anti-fosfatidilserina e anti-protrombina. O anticorpo anti-Sm foi igualmente determinado por ELISA e o anti-DNA dupla hélice, por imunofluorescência indireta. Avaliamos clinicamente à ocorrência de tromboses arterial e venosa. A frequência pré-vacinação de pelo menos um anticorpo antifosfolípide foi significativamente maior nos pacientes com SAF primária comparados aos controles (58% vs 24%, p = 0,0052). A frequência global de anticorpos antifosfolípides pré-vacinação e 03 semanas e 06 meses após a vacinação permaneceu inalterada tanto em pacientes (p = 0,89) como em controles (p = 0,83). A frequência de cada anticorpo específico nos dois grupos permaneceu estável nas três avaliações (p > 0,05). A frequência de cada anticorpo mantevese invariável nos pacientes tratados com cloroquina (p > 0,05). Em 3 semanas, 2 pacientes com SAF primária deselvolveram um anticorpo antifosfolípide novo porém transitório (aCL IgG e IgM), enquanto que em 6 meses novos anticorpos foram observados em 6 pacientes e nenhum apresentou altos títulos. Anti-Sm e anti-DNA dupla hélice foram negativos e nenhuma nova trombose arterial ou venosa foi observada durante o estudo. Este foi o primeiro estudo a demonstrar que a vacina contra influenza pandêmica em pacientes com SAF primária não induz tromboses e uma produção significante de anticorpos antifosfolípides a curto e longo prazos. (ClinicalTrials.gov, #NCT01151644). / Chronic rheumatic disease patients exhibit an increased risk for infections. Therefore, vaccination is imperative. Antiphospholipid antibodies (aPL) and thrombosis triggering after infections and vaccination in this population were reported, except for primary antiphospholipd syndrome (PAPS). Study\'s main objective was short and long-term evaluation of a panel of antiphospholipid autoantibodies following pandemic influenza A/H1N1 non-adjuvant vaccine in primary antiphospholipid syndrome patients and healthy controls. Forty-five PAPS and 33 healthy controls were immunized with A/H1N1 pandemic influenza vaccine. They were prospectively assessed at pre-vaccination, 3 weeks and 6 months after vaccination. aPL autoantibodies were determined by an enzyme-linked immunosorbent assay (ELISA) and included IgG/IgM: anticardiolipin (aCL), anti-beta2GPI; anti-annexin V, anti-phosphatidyl serine and antiprothrombin antibodies. Anti-Sm was determined by ELISA and anti-dsDNA by indirect immunfluorescence. Arterial and venous thrombosis were also clinically assessed. Pre-vaccination frequency of at least one aPL antibody was significantly higher in PAPS patients versus controls (58% vs. 24%, p=0.0052). The overall frequencies of aPL antibody at pre-vaccination, 3 weeks and 6 months after immunization remained unchanged in patients (p=0.89) and controls (p=0.83). The frequency of each antibody specificity for patients and controls remained stable in the three evaluated period (p > 0.05). The frequency of each antibody kept invariable in PAPS patients under chloroquine treatment (p > 0.05). At 3 weeks, 2 PAPS patients developed a new but transient aPL antibody (aCL IgG and IgM), whereas at 6 months new aPL antibodies were observed in 6 PAPS patients and none had high titer. Anti-Sm and anti-dsDNA autoantibodies were uniformly negative and no new arterial or venous thrombosis were observed throughout the study. This was the first study to demonstrate that pandemic influenza vaccine in PAPS patients does not trigger short and long-term thrombosis or a significant production of aPL related antibodies. (ClinicalTrials.gov, #NCT01151644)